Fibroblastic reticular cells and their role in viral hemorrhagic fevers

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 4, 2009, Pages 423-435

  Steele, Keith E ^a   Anderson, Arthur O ^a   Mohamadzadeh, Mansour ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Ebola virus; Fibroblastic reticular cell; Lassa virus; Marburg virus; Viral hemmorrhagic fever

Indexed keywords

EBOLA VACCINE; VIRUS ANTIGEN; CYTOKINE;

ARENAVIRUS; CELL ACTIVITY; CLINICAL FEATURE; CYTOLOGY; DISEASE COURSE; EBOLA VIRUS; FIBROBLASTIC RETICULAR CELL; FILOVIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LASSA FEVER; NONHUMAN; PATHOGENESIS; RETICULUM CELL; REVIEW; RISK FACTOR; VACCINATION; VIRUS HEMORRHAGIC FEVER; ANIMAL; BIOLOGICAL MODEL; FIBROBLAST; IMMUNOLOGY; INNATE IMMUNITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS INFECTION;

ANIMALS; ARENAVIRIDAE INFECTIONS; CYTOKINES; FIBROBLASTS; FILOVIRIDAE INFECTIONS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; IMMUNITY, INNATE; LASSA FEVER; MODELS, BIOLOGICAL;

EID: 85047682497     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.13     Document Type: Review

References (127)

1. Update: outbreak of Ebola viral hemorrhagic fever - Zaire, 1995. MMWR Morb. Mortal. Wkly Rep. 44(25), 468-469, 475 (1995).
2. Jahrling PB, Marty AM, Geisbert TW. Viral hemorrhagic fevers. In: Textbooks of Military Medicine - Medical Aspects of Biological Warfare. Dembek ZF (Ed.). Borden Institute Office of the Surgeon General United States Army Medical Dept. Center and School, Washington, DC, USA Falls Church, VA, USA. Fort Sam, Houston, TX, USA 271-310 (2007).
3. Warfield KL JN, Deal EM, Swenson DL, Larsen T, Bavari S. Viral Hemorrhagic Fevers. In: Biodefense: Research Methodology and Animal Models. Swearengen JR (Ed.). CRC Press, FL, USA (2006).
4. Khan SH, Goba A, Chu M et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 78(1), 103-115 (2008).
5. Baize S, Leroy EM, Georges AJ et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128(1), 163-168 (2002).
6. Baize S, Leroy EM, Georges-Courbot MC et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5(4), 423-426 (1999).
7. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 5(1), 5-7 (2000).
8. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 125(4), 243-253 (2001).
9. Chen JP, Cosgriff TM. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul. Fibrinolysis 11(5), 461-483 (2000).
10. Fisher-Hoch SP, Platt GS, Neild GH et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J. Infect. Dis. 152(5), 887-894 (1985).
11. Geisbert TW, Hensley LE, Jahrling PB et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362(9400), 1953-1958 (2003).
12. Geisbert TW, Young HA, Jahrling PB et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188(11), 1618-1629 (2003).
13. Hensley LE, Geisbert TW. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb. Haemost. 94(2), 254-261 (2005).
14. Wahl-Jensen V, Kurz SK, Hazelton PR et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol. 79(4), 2413-2419 (2005).
15. Baize S, Kaplon J, Faure C et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172(5), 2861-2869 (2004).
16. Davis KJ, Anderson AO, Geisbert TW et al. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch. Pathol. Lab. Med. 121(8), 805-819 (1997).
17. Feldmann H, Bugany H, Manner F et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70(4), 2208-2214 (1996).
18. Geisbert TW, Hensley LE, Larsen T et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163(6), 2347-2370 (2003).
19. Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct. Pathol. 22(1), 3-17 (1998).
20. Jaax NK, Davis KJ, Geisbert TJ et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 120(2), 140-155 (1996).
21. Mohamadzadeh M, Chen L, Olinger GG, Pratt WD, Schmaljohn AL. Filoviruses and the balance of innate, adaptive, and inflammatory responses. Viral Immunol. 19(4), 602-612 (2006).
22. Takada A, Fujioka K, Tsuiji M et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78(6), 2943-2947 (2004).
23. Gibb TR, Bray M, Geisbert TW et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125(4), 233-242 (2001).
24. Steele K, Crise B, Kuehne A, Kell W. Ebola virus glycoprotein demonstrates differential cellular localization in infected cell types of nonhuman primates and guinea pigs. Arch. Pathol. Lab. Med. 125(5), 625-630 (2001).
25. Siegert R, Shu HL, Slenczka W. [Isolation and identification of the "Marburg virus"]. Dtsch. Med. Wochenschr. 93(12), 604-612 (1968).
26. International Committee on Taxonomy of Viruses. Van Regenmortel MHV, International Union of Microbiological Societies. Virology Division. Virus taxonomy: Eighth report of the International Committee on Taxonomy of Viruses. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (Eds). Academic Press, CA, USA (2005).
27. Johnson ED, Johnson BBC, Silverstein D et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. 11(Suppl.), 101-114 (1996).
28. Towner JS, Khristova ML, Sealy TK et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80(13), 6497-6516 (2006).
29. Schmaljohn A, Hevey M. Medical countermeasures for Filoviruses and other viral agents. In: Biological Weapons Defense: Infectious Disease Counterbioterrorism. Lindler LE, Lebeda FJ, Korch G (Eds). Humana Press, NJ, USA 239-253 (2004).
30. Groseth A, Feldmann H, Theriault S, Mehmetoglu G, Flick R. RNA polymerase I-driven minigenome system for Ebola viruses. J. Virol. 79(7), 4425-4433 (2005).
31. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73(3), 2333-2342 (1999).
32. Dolnik O, Volchkova V, Garten W et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 23(10), 2175-2184 (2004).
33. Feldmann H, Volchkov VE, Volchkova VA, Klenk HD. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch. Virol. 15(Suppl.), 159-169 (1999).
34. Volchkov VE, Volchkova VA, Dolnik O, Feldmann H, Klenk HD. Polymorphism of filovirus glycoproteins. Adv. Virus Res. 64, 359-381 (2005).
35. Volchkov VE, Volchkova VA, Stroher U et al. Proteolytic processing of Marburg virus glycoprotein. Virology 268(1), 1-6 (2000).
36. Borio L, Inglesby T, Peters CJ et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287(18), 2391-2405 (2002).
37. Bwaka MA, Bonnet MJ, Calain P et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 179(Suppl. 1), S1-S7 (1999).
38. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. The pathology of experimental Ebola virus infection in monkeys. J. Pathol. 125(3), 131-138 (1978).
39. Gear JH. Hemorrhagic fevers, with special reference to recent outbreaks in southern Africa. Rev. Infect. Dis. 1(4), 571-591 (1979).
40. Martini GA, Siegert R. Marburg Virus Disease. Springer-Verlag, Berlin, Germany, and NY, USA (1971).
41. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179(Suppl. 1), S199-S202 (1999).
42. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251(1), 28-37 (1998).
43. Kash JC, Muhlberger E, Carter V et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80(6), 3009-3020 (2006).
44. Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 25(11), 1923-1934 (2007).
45. Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 4(4), 281-297 (2005).
46. Schmaljohn C, Nabel GJ, McCormick JJ, Schmaljohn A. Vaccines for hantaviruses, Lassa virus and filoviruses. In: New Generation Vaccines. Levine, MM (Ed.). Taylor & Francis, NY, USA and London, UK 679-694 (2004).
47. Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11(7), 786-790 (2005).
48. Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21(25-26), 4071-4080 (2003).
49. Sullivan NJ, Geisbert TW, Geisbert JB et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3(6), e177 (2006).
50. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812), 605-609 (2000).
51. Hart MK. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33 (5-6), 583-595 (2003).
52. Bukreyev A, Yang L, Zaki SR et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80(5), 2267-2279 (2006).
53. Geisbert TW, Pushko P, Anderson K et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8(5), 503-507 (2002).
54. Hevey M, Negley D, VanderZanden L et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20(3-4), 586-593 (2001).
55. Warfield KL, Swenson DL, Demmin G, Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev. Vaccines 4(3), 429-440 (2005).
56. Warfield KL, Swenson DL, Olinger GG et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2(1), e1 (2006).
57. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239(1), 206-216 (1997).
58. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76(12), 6408-6412 (2002).
59. Wilson JA, Hevey M, Bakken R et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287(5458), 1664-1666 (2000).
60. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82(Pt 6), 1365-1373 (2001).
61. Bray M, Raymond JL, Geisbert T, Baker RO. 3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res. 55(1), 151-159 (2002).
62. Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol. 7(7), 556-567 (2007).
63. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol. 124(3), 453-460 (2001).
64. Bosio CM, Aman MJ, Grogan C et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188(11), 1630-1638 (2003).
65. Mahanty S, Hutchinson K, Agarwal S et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170(6), 2797-2801 (2003).
66. Geisbert TW, Hensley LE, Gibb TR et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80(2), 171-186 (2000).
67. Geisbert TW, Jones S, Fritz EA et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2(6), e183 (2005).
68. de Manzione N, Salas RA, Paredes H et al. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin. Infect. Dis. 26(2), 308-313 (1998).
69. Peters CJ. Emerging infections: lessons from the viral hemorrhagic fevers. Trans. Am. Clin. Climatol. Assoc. 117, 189-197 (2006).
70. Gunther S, Lenz O. Lassa virus. Crit. Rev. Clin. Lab. Sci. 41(4), 339-390 (2004).
71. Edington GM, White HA. The pathology of Lassa fever. Trans. R. Soc. Trop. Med. Hyg. 66(3), 381-389 (1972).
72. Winn WC Jr. Walker DH. The pathology of human Lassa fever. Bull. World Health Organ. 52(4-6), 535-545 (1975).
73. Walker DH, Murphy FA. Pathology and pathogenesis of arenavirus infections. Curr. Top. Microbiol. Immunol. 133, 89-113 (1987).
74. Baize S, Pannetier D, Faure C et al. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 8(5), 1194-1202 (2006).
75. Lukashevich IS, Maryankova R, Vladyko AS et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-α gene expression. J. Med. Virol. 59(4), 552-560 (1999).
76. Carrion R Jr, Brasky K, Mansfield K et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J. Virol. 81(12), 6482-6490 (2007).
77. Callis RT, Jahrling PB, DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 31(5), 1038-1045 (1982).
78. Jahrling PB, Smith S, Hesse RA, Rhoderick JB. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 37(2), 771-778 (1982).
79. Anderson AO, Anderson ND. Studies on the structure and permeability of the microvasculature in normal rat lymph nodes. Am. J. Pathol. 80 (3), 387-418 (1975).
80. Anderson AO, Shaw S. T cell adhesion to endothelium: the FRC conduit system and other anatomic and molecular features which facilitate the adhesion cascade in lymph node. Semin. Immunol. 5(4), 271-282 (1993).
81. Chilosi M, Menestrina F, Pizzolo G et al. Fluoride resistant α-naphthyl acetate esterase and combined enzyme histochemistry in the study of normal and pathologic lymphoid tissues. Basic Appl. Histochem. 25(1), 39-50 (1981).
82. Clark SL Jr. The reticulum of lymph nodes in mice studied with the electron microscope. Am. J. Anat. 110, 217-257 (1962).
83. Gretz JE, Anderson AO, Shaw S. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol Rev. 156, 11-24 (1997).
84. Gretz JE, Kaldjian EP, Anderson AO, Shaw S. Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. J. Immunol. 157(2), 495-499 (1996).
85. Hayakawa M, Kobayashi M, Hoshino T. Direct contact between reticular fibers and migratory cells in the paracortex of mouse lymph nodes: a morphological and quantitative study. Arch. Histol. Cytol. 51(3), 233-240 (1988).
86. Moe RE. Fine structure of the reticulum and sinuses of lymph nodes. Am. J. Anat. 112, 311-335 (1963).
87. Link A, Vogt TK, Favre S et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8(11), 1255-1265 (2007).
88. Lokmic Z, Lammermann T, Sixt M et al. The extracellular matrix of the spleen as a potential organizer of immune cell compartments. Semin. Immunol. 20(1), 4-13 (2008).
89. Nolte MA, Belien JA, Schadee-Eestermans I et al. A conduit system distributes chemokines and small blood-borne molecules through the splenic white pulp. J. Exp. Med. 198(3), 505-512 (2003).
90. Willard-Mack CL. Normal structure, function, and histology of lymph nodes. Toxicol. Pathol. 34(5), 409-424 (2006).
91. Kaldjian EP, Gretz JE, Anderson AO, Shi Y, Shaw S. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int. Immunol. 13(10), 1243-1253 (2001).
92. Sixt M, Kanazawa N, Selg M et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22(1), 19-29 (2005).
93. Bajenoff M, Egen JG, Koo LY et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 25(6), 989-1001 (2006).
94. Mueller SN, Matloubian M, Clemens DM et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl Acad. Sci. USA 104(39), 15430-15435 (2007).
95. Van Vliet E, Melis M, Foidart JM, Van Ewijk W. Reticular fibroblasts in peripheral lymphoid organs identified by a monoclonal antibody. J. Histochem. Cytochem. 34(7), 883-890 (1986).
96. Gloghini A, Volpe R, Carbone A. Vimentin immunostaining in fibroblastic reticulum cells within human reactive and neoplastic lymphoid follicles. Hum. Pathol. 21(8), 792-798 (1990).
97. Michie SA, Sweeter PR, Bolt PA, Butcher EC, Picker LJ. The human peripheral lymph node vascular addressin. An inducible endothelial antigen involved in lymphocyte homing. Am. J. Pathol. 143(6), 1688-1698 (1993).
98. Steele KE, Anderson AO, Mohamadzadeh M. Fibroblastic reticular cell infection by hemorrhagic fever viruses. Immunotherapy 1(2), 187-197 (2009).
99. Hempstead BL. The many faces of p75NTR. Curr. Opin. Neurobiol. 12(3), 260-267 (2002).
100. Clark RA, Alon R, Springer TA. CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma. J. Cell Biol. 134(4), 1075-1087 (1996).
101. Ruco LP, Pomponi D, Pigott R et al. Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease. Am. J. Pathol. 140(6), 1337-1344 (1992).
102. Hara T, Katakai T, Lee JH et al. A transmembrane chemokine, CXC chemokine ligand 16, expressed by lymph node fibroblastic reticular cells has the potential to regulate T cell migration and adhesion. Int. Immunol. 18(2), 301-311 (2006).
103. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 3(10), e3331 (2008).
104. Vega F, Coombes KR, Thomazy VA et al. Tissue-specific function of lymph node fibroblastic reticulum cells. Pathobiology 73(2), 71-81 (2006).
105. Baekkevold ES, Yamanaka T, Palframan RT et al. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J. Exp. Med. 193(9), 1105-1112 (2001).
106. Mueller SN, Hosiawa-Meagher KA, Konieczny BT et al. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317(5838), 670-674 (2007).
107. Boyman O, Purton JF, Surh CD, Sprent J. Cytokines and T-cell homeostasis. Curr. Opin. Immunol. 19(3), 320-326 (2007).
108. Kittipatarin C, Khaled AR. Interlinking interleukin-7. Cytokine 39(1), 75-83 (2007).
109. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 8(5), 362-371 (2008).
110. Thomazy VA, Vega F, Medeiros LJ, Davies PJ, Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: tissue transglutaminase reveals coordinate regulation of multiple cell types. Am. J. Pathol. 163(1), 165-174 (2003).
111. Bofill M, Akbar AN, Amlot PL. Follicular dendritic cells share a membrane-bound protein with fibroblasts. J. Pathol. 191(2), 217-226 (2000).
112. Bajenoff M, Glaichenhaus N, Germain RN. Fibroblastic reticular cells guide T lymphocyte entry into and migration within the splenic T cell zone. J. Immunol. 181(6), 3947-3954 (2008).
113. Gregoire C, Cognet C, Chasson L et al. Intrasplenic trafficking of natural killer cells is redirected by chemokines upon inflammation. Eur. J. Immunol. 38(8), 2076-2084 (2008).
114. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J. Exp. Med. 192(10), 1425-1440 (2000).
115. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J. Exp. Med. 200(6), 783-795 (2004).
116. Palframan RT, Jung S, Cheng G et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J. Exp. Med. 194(9), 1361-1373 (2001).
117. Anderson AO, Shaw S. Conduit for privileged communications in the lymph node. Immunity 22(1), 3-5 (2005).
118. Itano AA, McSorley SJ, Reinhardt RL et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19(1), 47-57 (2003).
119. Scandella E, Bolinger B, Lattmann E et al. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat. Immunol. 9(6), 667-675 (2008).
120. Djavani MM, Crasta OR, Zapata JC et al. Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol. 81(15), 7960-7973 (2007).
121. Lukashevich IS, Djavani M, Rodas JD et al. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J. Med. Virol. 67(2), 171-186 (2002).
122. Hsu KM, Pratt JR, Akers WJ, Achilefu SI, Yokoyama WM. Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J. Gen. Virol. 90 (Pt 1), 33-43 (2009).
123. Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr. Mol. Med. 5(8), 761-772 (2005).
124. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80(3), 169-179 (2002).
125. Bergamini CM, Griffin M, Pansini FS. Transglutaminase and vascular biology: physiopathologic implications and perspectives for therapeutic interventions. Curr. Med. Chem. 12(20), 2357-2372 (2005).
126. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit. Rev. Clin. Lab. Sci. 33(5), 357-421 (1996).
127. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncology 7(4), 452-464 (2005).